Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus

Lupus

Volumn 17, Issue 3, 2008, Pages 210-214

  Fukushima, Toshihiro ^a   Dong, Lingli ^a,b   Sakai, T ^a   Sawaki, T ^a   Miki, M ^a   Tanaka, M ^a   Masaki, Y ^a   Hirose, Y ^a   Kuwana, M ^c   Umehara, H ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amegakaryocytic thrombocytopenia; Rituximab (anti CD20 mAb); SLE

Indexed keywords

ANTIVIRUS AGENT; AUTOANTIBODY; C MPL ANTIBODY; CYCLOSPORIN A; INSULIN RECEPTOR ANTIBODY; PREDNISOLONE; RITUXIMAB; THROMBOPOIETIN RECEPTOR;

ADULT; AMEGAKARYOCYTIC THROMBOCYTOPENIA; ARTICLE; ASCITES; CASE REPORT; CHYLOTHORAX; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; EDEMA; FEMALE; HUMAN; MEGAKARYOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; PSYCHOSIS; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOANTIBODIES; BLOOD PLATELETS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEGAKARYOCYTES; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA;

EID: 42549109125     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307086032     Document Type: Article

References (14)

1. Singh, RR. SLE: translating lessons from model systems to human disease. Trends Immunol 2005; 26: 572-579.
2. Croker, JA, Kimberly, RP. SLE: challenges and candidates in human disease. Trends Immunol 2005; 26: 580-586.
3. Edwards, JC, Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.
4. Kuwana, M, Kaburaki, J, Okazaki, Y, Miyazaki, H, Ikeda, Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45: 851-854.
5. Agarwal, N, Spahr, JE, Werner, TL, Newton, DL, Rodgers, GM. Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol 2006; 81: 132-135.
6. Tristano, AG. Acquired amegakaryocytic thrombocytopenic purpura: review of a not very well-defined disorder. Eur J Intern Med 2005; 16: 477-481.
7. Wendling, F, Maraskovsky, E, Debili, N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571-574.
8. Kuwana, M, Okazaki, Y, Kajihara, M, et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 2002; 46: 2148-2159.
9. Looney, RJ, Anolik, J, Sanz, I. New therapies for systemic lupus erythematosus: cellular targets. Rheum Dis Clin North Am 2006; 32: 201-15, xi.
10. Tanaka, Y, Yamamoto, K, Takeuchi, T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17: 191-197.
11. Vallerskog, T, Gunnarsson, I, Widhe, M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74.
12. Anolik, JH, Barnard, J, Cappione, A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590.
13. Sun, LY, Zhang, HY, Feng, XB, Hou, YY, Lu, LW, Fan, LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 121-128.
14. Stasi, R, Pagano, A, Stipa, E, Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.